Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company''s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Latest shares articles
Nasdaq 100: Trading US CPI
Futures up on Nvidia’s China sales resumption of AI chips, but the next test is US pricing data.
06:29, 15 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:58, 14 July 2025
Top 5 biggest short squeezes
Explore five iconic short squeeze cases like GameStop & Tesla. Learn how positioning, sentiment & timing drive dramatic market moves.
15:09, 14 July 2025
Nvidia stock forecast: Third-party price target
Discover third-party Nvidia stock forecast predictions for 2025-2030 and beyond, with analyst targets, historical prices, and trading strategies.
15:41, 11 July 2025
Ratings and Reviews
Ratings and Reviews
